The ANKFY1 Knockout HeLa Polyclonal Cells product provides a heterogeneous population of CRISPR/Cas9-edited human cervical adenocarcinoma cells carrying targeted disruption of the ANKFY1 gene. This polyclonal knockout pool eliminates the need for single-cell cloning while enabling loss-of-function studies of ANKFY1 in an immortalized epithelial background. The cells are supplied as a ready-to-use polyclonal knockout cell population, suitable for investigating endosomal trafficking and receptor recycling mechanisms.
HeLa cells, derived from a HPV-18 positive cervical adenocarcinoma, represent one of the most extensively characterized human cancer cell lines. Their robust growth, ease of transfection, and well-documented endocytic pathways make them an ideal host for dissecting membrane trafficking events. The parental HeLa line retains functional EGFR signaling, transferrin receptor cycling, and endosomal sorting machinery, providing a physiologically relevant context for analyzing ANKFY1-dependent processes.
ANKFY1 (Ankyrin Repeat and FYVE Domain Containing 1) encodes a Rab5 effector protein that localizes to early endosomes via its FYVE domain binding to phosphatidylinositol 3-phosphate (PI3P). As a scaffold, ANKFY1 coordinates endosomal trafficking and recycling of internalized receptors, including EGFR and the transferrin receptor. Its activity is regulated by upstream PI3K and EGFR activation, and it interacts with endosomal sorting complexes (ESCRT components) to mediate cargo sorting. In the broader signaling network, ANKFY1 operates within the endocytic recycling pathway alongside Rab5, Rab11, and PI3K, influencing the fate and signaling output of endocytosed receptors.
Disruption of ANKFY1 in HeLa cells compromises the recycling of cargo from early endosomes back to the plasma membrane, leading to altered receptor degradation kinetics and perturbed signal transduction. Since HeLa cells exhibit active EGFR internalization and trafficking, ANKFY1 knockout provides a valuable model to study how endosomal sorting defects affect cancer cell proliferation and response to growth factors. The polyclonal population retains the genetic heterogeneity of the knockout, reflecting a more physiologically relevant cellular context compared to single clones.
These knockout cells are designed for a range of experimental applications, including endosomal trafficking studies using transferrin uptake and recycling assays, EGFR degradation kinetics by western blotting or flow cytometry, and immunofluorescence localization of endosomal markers. They can be employed to dissect the role of ANKFY1 in receptor-mediated signaling and to screen for compounds targeting endocytic pathways in cancer. Researchers can also use RT-qPCR to confirm gene disruption and assess downstream transcriptional effects. For additional product details or technical support, please contact Ascent Research.
